Relationship between a pro- and anti-inflammatory cytokine imbalance and depression in haemodialysis patients

European Cytokine Network

Volumn 23, Issue 4, 2012, Pages 179-186

  Taraz, Mohammad ^a   Khatami, Mohammad Reza ^b   Gharekhani, Afshin ^a   Abdollahi, Alireza ^b   Khalili, Hossein ^a   Dashti Khavidaki, Simin ^a,b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Anti inflammatory cytokines; Depression; Haemodialysis; Haemoglobin; Pro inflammatory cytokines

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CALCIUM ION; CYTOKINE; FERRITIN; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRANSFERRIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BECK DEPRESSION INVENTORY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEPRESSION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PHOSPHATE BLOOD LEVEL; PREVALENCE; QUESTIONNAIRE; SENSITIVITY AND SPECIFICITY; URIC ACID BLOOD LEVEL;

ANTI-INFLAMMATORY CYTOKINES; DEPRESSION; HAEMODIALYSIS; HAEMOGLOBIN; PRO-INFLAMMATORY CYTOKINES;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; CASE-CONTROL STUDIES; CYTOKINES; DEMOGRAPHY; DEPRESSION; FEMALE; HUMANS; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; RENAL DIALYSIS; YOUNG ADULT;

EID: 84873738300     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: 10.1684/ecn.2013.0326     Document Type: Article

References (55)

1. Kimmel PL, Peterson RA. Depression in end-stage renal disease patients treated with hemodialysis: tools, correlates, outcomes, and needs. Semin Dial 2005; 18: 91-7.
2. Lopes AA, Bragg J, Young E, et al. Depression as a predictor of mortality and hospitalization among hemodialysis patients in the United States and Europe. Kidney Int 2002; 62: 199-207.
3. Hedayati SS, Bosworth HB, Briley LP, et al. Death and hospitalization of patients on chronic hemodialysis is associated with a physician-based diagnosis of depression. Kidney Int 2008; 74: 930-6.
4. Herbelin A, Urena P, Nguyen AT, et al. Elevated circulating levels of interleukin-6 in patients with chronic renal failure. Kidney Int 1991; 39: 954-60.
5. Pereira BJ, Shapiro L, King AJ, et al. Plasma levels of IL-1β, TNF-α and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients. Kidney Int 1994; 45: 890-6.
6. Stenuinkel P, Alvestrand A. Inflammation in end-stage renal disease: sources, consequences and therapy. Semin Dial 2002; 15: 329-37.
7. Barreto DV, Barreto FC, Liabeuf S, et al. Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. Kidney Int 2010; 77: 550-6.
8. Lanquillon S, Krieg JC, Bening-Abu-Shach U, et al. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 2000; 22: 370-9.
9. Anisman H, Merali Z, Poulter MD, et al. Cytokines as a precipitant of depressive illness: animal and human studies. Curr Pharm Des 2005; 11: 963-72.
10. Schiepers OJ, Wichers MC, Maes M. Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 201-17.
11. Mohr DC, Goodkin DE, Islar J, et al. Treatment of depression is associated with suppression of nonspecific and antigen-specific T(H)1 responses in multiple sclerosis. Arch Neurol 2001; 58: 1081-6.
12. Kalender B, Ozdemir AC, Koroglu G. Association of depression with markers of nutrition and inflammation in chronic kidney disease and end stage renal disease. Nephron Clin Pract 2006; 102: 115-21.
13. Hung KC, Wu CC, Chen HS, et al. Serum IL-6, albumin and comorbidities are closely correlated with symptoms of depression in patients on maintenance haemodialysis. Nephrol Dial Transplant 2011; 26: 658-64.
14. Frommberger UH, Bauer J, Haselbauer P, et al. Interleukin-6 plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur. Arch. Psychiatry. Clin Neurosci 1977; 274: 228-33.
15. Sonikian M, Metaxaki P, Papavasileiou D, et al. Effects of Interleukin-6 on Depression Risk in Dialysis Patients. Am J Nephrol 2010; 31: 303-8.
16. Montinaro V, Iaffaldano GP, Granata S, et al. Emotional symptoms, quality of life and cytokine profile in hemodialysis patients. Clin Nephrol 2010; 73: 36-43.
17. Dervisoglu E, Kir HM, Kalender B, et al. Depressive Symptoms and Proinflammatory Cytokine Levels in Chronic Renal Failure Patients. Nephron Clin Pract 2008; 108: 272-7.
18. Kalender B, Dervisoglu E, Sengul E, et al. Depression, nutritional status, and serum cytokines in peritoneal dialysis patients: is there a relationship? Perit Dial Int 2007; 27: 593-5.
19. Craven JL, Rodin GM, Littlefield C. The Beck Depression Inventory as a screening device for major depression in renal dialysis patients. Int J Psychiatry Med 1988; 18: 365-74.
20. Ghasemzadeh H, Mojtabai R, Karamghadiri N, et al. psychometric properties of Persian-language version of the beck depression inventory-second edition: BDI-II-Persian. Depress Anxiety 2005; 21: 185-192.
21. Caglar K, Peng Y, Pupim LB, et al. Inflammatory signals associated with hemodialysis. Kidney Int 2002; 62: 1408-1416.
22. Kato A, Odamaki M, Takita T, et al. Association between interleukin-6 and carotid atherosclerosis in hemodialysis patients. Kidney Int 2002; 61: 1143-1152.
23. Hedayati SS, Minhajuddin AT, Toto RD, et al. Prevalence of major depressive episode in CKD. Am J Kidney Dis 2009; 54: 424-432.
24. Troidle L, Watnick S, Wuerth DB, et al. Depression and its association with peritonitis in long-term peritoneal dialysis patients. Am J Kidney Dis 2003; 42: 350-354.
25. Anisman H, Hayley S, Turrin N, et al. Cytokines as a stressor: Implications for depressive illness. Int J Neuropsychopharmacol 2002; 5:357-373.
26. Bonaccorso S, Marino V, Puzella A, et al. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J Clin Psychopharmacol 2002; 22: 86-90.
27. Bosolla M, Lucian G, Tazza L. Fatigue and its correlates in chronic hemodialysis patients. Blood Purif 2009; 28: 245-52.
28. Rao M, Guo D, PerianayagamMCet al. Plasma interleukin-6 predicts cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2005; 45:324-333.
29. Stenvinkel P, Heimburger O, Jogestrand T. Elevated interleukin-6 predicts progressive carotid artery atherosclerosis in dialysis patients: association with Chlamydia pneumonia seropositivity. Am J Kidney Dis 2002; 39:274-282.
30. Stompor T, Pasowicz M, SullowiczW, et al.: An association between coronary artery calcification score, lipid profile, and selected markers of chronic inflammation in ESRD patients treated with peritoneal dialysis. Am J Kidney Dis 2003; 41:203-211.
31. Moorman AJ, Mozaffarian D, Wilkinson CW, et al. In patients with heart failure elevated soluble TNF-receptor 1 is associated with higher risk of depression. J Card Fail 2007; 13: 738-43.
32. Tuglu C, Kara SH, Caliyurt O, et al. Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology 2003; 170: 429-33.
33. Cilan H, Oguzhan N, Unal A, et al. Relationship between depression and proinflammatory cytokine levels in hemodialysis patients. Ren Fail 2012; 34: 275-8.
34. Ko GJ, Kim MG, Yu YM, et al. Association between depression symptoms with inflammation and cardiovascular risk factors in patients undergoing peritoneal dialysis. Nephron Clin Pract 2010; 116: 29-35.
35. Wakkach A, Cottrez F, Groux H. Can interleukin-10 be used as a true immunoregulatory cytokine? Eur Cytokine Netw 2000; 11: 153-60.
36. Tedgui A, Mallat Z. Anti-inflammatory mechanisms in the vascular wall. Circ Res 2001; 88: 877-87.
37. Tziakas DN, Chalikias GK, Antonoglou CO, et al. Apolipoprotein E genotype and circulating interleukin-10 levels in patients with stable and unstable coronary artery disease. J Am Coll Cardiol 2006; 48: 2471-81.
38. Kilic T, Ural D, Ural E, et al. Relation between proinflammatory to anti-inflammatory cytokine ratios and longterm prognosis in patients with non-ST elevation acute coronary syndrome. Heart 2006; 92: 1041-6.
39. Opp MR, Smith EM, Hughes TK Jr. Interleukin-10 (cytokine synthesis inhibitory factor) acts in the central nervous system of rats to reduce sleep. J Neuroimmunol 1995; 60: 165-8.
40. Kubera M, Lin AH, Kenis G, et al. Anti-inflammatory effects of antidepressants through suppression of the interferongamma/ interleukin-10 production ratio. J Clin Psychopharmacol 2001; 21: 199-206.
41. Maes M, Song C, Lin AH, et al. Negative immunoregulatory effects of antidepressants: inhibition of interferon-gamma and stimulation of interleukin-10 secretion. Neuropsychopharmacology 1999; 20: 370-9.
42. Kenis G, MaesM. Effects of antidepressants on the production of cytokines. Int J Neuropsychopharmacol 2002; 5:401-412
43. Brunet P, Capo C, Dellacasagrande J, Thirion X, Mege J, Berland Y. IL-10 synthesis and secretion by peripheral blood mononuclear cells in haemodialysed patients. Nephrol Dial Transplant 1998; 13: 1745-1751.
44. Turner DM, Williams MD, Sankaran D, et al. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997; 24: 1-8.
45. Holtzman S, Abbey SE, Chan C, et al. A genetic predisposition to produce low levels of IL-10 is related to depressive symptoms: a pilot study of patients with end stage renal disease. Psychosomatics 2012; 53: 155-61.
46. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: Inflammation and the pathogenesis of depression. Trends Immunol 2006; 27: 24-31.
47. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: The role of cytokines in the pathophysiology of major depression. Biol Psychiatry 2009; 65: 732-41.
48. Müller N, Schwarz MJ. The immune-mediated alteration of serotonin and glutamate: towards anintegrated view of depression. Mol Psychiatry 2007; 12: 988-1000.
49. Raison CL, Borisov AS, Woolwine BJ, et al. Interferon-alpha effects on diurnal hypothalamic-pituitary-adrenal axis activity: relationship with pro-inflammatory cytokines and behavior. Mol Psychiatry 2010; 15: 535-47.
50. Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: Double-blind placebo-controlled randomized phase III trial. Lancet 2006; 367: 29-35.
51. Goicoechea M, Martin J, Sequera PD, et al. Role of cytokines in the response to erythropoietin in hemodialysis patients. Kidney Int 1998; 54: 1337-43.
52. Macdougall IC, Allen DA, Cavill I, et al. Poor response to erythropoietin in inflammatory conditions may be mediated by interleukin-6. Nephrol Dial Transplant 1994; 9: 1033.
53. Rosenlof K, Kivivuori SM, Gronhagen-Riska C, et al. Iron availability is transiently improved by intravenous iron medication in patients on chronic hemodialysis. Clin Nephrol 1995; 443: 249-55.
54. Guttridge DC, Mayo MW, Madrid LV, et al. NF-kappa B-induced loss of MaoD messenger RNA: possible role in muscle decay and cachexia. Science 2000; 289: 2363-6.
55. Ibrahim S, Salamony OEl. Depression, Quality of Life and Malnutrition-Inflammation Scores in Hemodialysis Patients. Am J Nephrol 2008; 28:784-791.